[1] Peng Q, Li H, Chen J, et al. Oral submucous fibrosis in Asian countries [J]. J Oral Pathol Med, 2020, 49(4):294-304. [2] Chhabra AK, Sune R, Reche A. Oral submucous fibrosis: A review of the current concepts in management [J]. Cureus, 2023, 15(10):e47259. [3] Peng Y, Ao M, Dong B, et al. Anti-inflammatory effects of curcumin in the inflammatory diseases: Status, limitations and countermeasures [J]. Drug Des Devel Ther, 2021, 15:4503-4525. [4] Gupta S, Ghosh S, Gupta S, et al. Effect of curcumin on the expression of p53, transforming growth factor-beta, and inducible nitric oxide synthase in oral submucous fibrosis: A pilot study [J]. J Investig Clin Dent, 2017, 8(4). [5] Kocaadam B, Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health [J]. Crit Rev Food Sci Nutr, 2017, 57(13):2889-2895. [6] Rai B, Kaur J, Jacobs R, et al. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress [J]. J Oral Sci, 2010, 52(2):251-256. [7] Zhang L, Tan J, Liu Y, et al. Curcumin relieves arecoline-induced oral submucous fibrosis via inhibiting the LTBP2/NF-kappaB axis [J]. Oral Dis, 2024, 30(4):2314-2324. [8] Chandrashekar A, Annigeri RG, Va U, et al. A clinicobiochemical evaluation of curcumin as gel and as buccal mucoadhesive patches in the management of oral submucous fibrosis [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 131(4):428-434. [9] Srivastava R, Kundu A, Pradhan D, et al. A comparative study to evaluate the efficacy of curcumin lozenges (turmnova) and intralesional corticosteroids with hyaluronidase in management of oral submucous fibrosis [J]. J Contemp Dent Pract, 2021, 22(7):751-755. [10] 黄丽丽,苏静.丹参的作用机制及临床应用研究进展[J].中国药物滥用防治杂志,2023,29(6):1002-1006. [11] Zheng L, Guan ZJ, Pan WT, et al. Tanshinone suppresses arecoline-induced epithelial-mesenchymal transition in oral submucous fibrosis by epigenetically reactivating the p53 pathway [J]. Oncol Res, 2018, 26(3):483-494. [12] 杨博,吕娇,张雪梅,等.丹参对大鼠口腔黏膜下纤维化的治疗效果[J].武警医学,2023,34(7):599-602. [13] 李涛.曲安奈德联合丹参酮注射液治疗口腔黏膜下纤维化的临床效果[J].临床医学研究与实践,2022,7(15):42-45. [14] 崔钰嘉,孙建勋,周学东.黄连素的生物学功能及治疗口腔疾病研究的进展[J].国际口腔医学杂志,2020,47(1):115-120. [15] 蔡少艾,胡明,汤晓燕,等.黄连素抗心脏纤维化作用及其机制[J].广东医学,2017,38(3):337-339. [16] 欧意桃,杨桂智,兰天,等.黄连素对小鼠肝纤维化的影响[J].安徽中医药大学学报,2017,36(2):51-55. [17] 万韬,刘国素.盐酸小檗碱对口腔黏膜成纤维细胞分化的影响[J].细胞与分子免疫学杂志,2011,27(4):440-441. [18] 姜钰婷,贺超,任田田,等.黄芩化学成分与药理作用研究进展[J].化工科技,2022,30(6):93-100. [19] 刘倩盼,邵翔,李玉婷,等.黄芩苷调节galectin-3/Akt/GSK-3β/Snail信号通路改善慢性肾脏病大鼠的肾纤维化机制[J].河北医药,2024,46(15):2261-2265. [20] 张伟,陈再欢,刘双春.肾靶向黄芩苷-溶菌酶结合物调控糖尿病肾病大鼠NF-κB信号通路改善肾脏纤维化作用机制探讨[J].社区医学杂志,2023,21(14):724-730. [21] 吴娟,刘苏杰,陈平平,等.黄芩苷通过抑制TLR4/MyD88/NF-κB信号通路减轻大鼠肝纤维化的作用[J].时珍国医国药,2023,34(3):549-553. [22] Channe P, Chavan M, Bhonde R, et al. Antifibrotic effect of baicalin on arecoline induced human oral fibroblast: An in-vitro study [J]. Asian Pac J Cancer Prev, 2024, 25(4):1349-1355. [23] 蔡蒋帆,唐建红.芦荟活性成分药理作用机制研究进展[J].世界最新医学信息文摘,2018,18(A2):122-125. [24] Anuradha A, Patil B, Asha VR. Evaluation of efficacy of aloe vera in the treatment of oral submucous fibrosis-a clinical study [J]. J Oral Pathol Med, 2017, 46(1):50-55. [25] Nerkar RA, Kulkarni TM, Shete A, et al. A comparative study to evaluate efficacy of curcumin and aloe vera gel along with oral physiotherapy in the management of oral submucous fibrosis: A randomized clinical trial [J]. Asian Pac J Cancer Prev, 2021, 22(S1):107-112. [26] Bohra A, Maheswari T, Harsh A, et al. Black turmeric and aloe vera in the management of oral submucous fibrosis: A prospective clinical study [J]. Asian Pac J Cancer Prev, 2021, 22(12):3941-3947. [27] Kao TC, Wu CH, Yen GC. Bioactivity and potential health benefits of licorice [J]. J Agric Food Chem, 2014, 62(3):542-553. [28] 温玉,付娆,刘城,等.甘草素调节Hippo/YAP/TAZ信号通路对高糖诱导的肾小球系膜细胞炎症反应及纤维化的影响[J].西部医学,2024,36(8):1131-1136. [29] 慕华,王亚兵.复方甘草酸苷注射液联合恩替卡韦对慢性乙肝患者肝功能及肝纤维化指标的影响[J].临床医学工程,2023,30(12):1691-1692. [30] James A, Gunasekaran N, Krishnan R, et al. Anti-fibrotic activity of licorice extract in comparison with colchicine on areca nut-induced fibroblasts: An in vitro study [J]. J Oral Maxillofac Pathol, 2022, 26(2):173-178. [31] Lee PH, Chu PM, Hsieh PL, et al. Glabridin inhibits the activation of myofibroblasts in human fibrotic buccal mucosal fibroblasts through TGF-beta/smad signaling [J]. Environ Toxicol, 2018, 33(2):248-255. |